Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials

JAMA

Volumn 282, Issue 24, 1999, Pages 2340-2346

  LaRosa, John C ^a   He, Jiang ^b   Vupputuri, Suma ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; LIPID; PLACEBO; STATIN;

ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

EID: 0033596281     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.24.2340     Document Type: Review

References (45)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383-1389.
2. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997;96:4211-4218.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. 1996;335:1001-1009.
5. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction. J Am Coll Cardiol. 1998;32:140-146.
6. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med. 1998;129:681-689.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
8. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.
9. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke. Lancet. 1995;346: 1647-1653.
10. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease. Ann Intern Med. 1996;124:515-517.
11. Schrott HG, Bittner V, Vittinghott E, et al. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. JAMA. 1997;277:1281-1286.
12. Vusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-98.
13. Cholesterol treatment Trialists' Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 1995;75:1130-1134.
14. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
15. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Circulation. 1998;97:946-952.
16. Sahni R, Maniet AR, Gerardo V, Banks VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991;121:1600-1608.
17. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I. Arch Intern Med. 1991;151:43-49.
18. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med. 1993;119:969-976.
19. Jones PH, Farmer JA, Cressman MD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia. Clin Cardiol. 1991;14:146-151.
20. The Pravastatin Multinational Study Group for Cardiac Risk Factors. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/ liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
21. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med. 1994;96:509-515.
22. LaRosa JC, Applegate W, Crouse JR III, et al. Cholesterol lowering in the elderly. Arch Intern Med. 1994; 154:529-539.
23. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
24. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study. Eur Heart J. 1994;15:255-269.
25. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary arteriography. Circulation. 1994;89:959-968.
26. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-1337.
27. Jukema JW, Bruschke AVG, van Boven ADJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 1995;91:2528-2540.
28. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1). J Am Coll Cardiol. 1995;26:1133-1139.
29. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
30. Salonen R, Nyyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). Circulation. 1995;92:1758-1764.
31. Lindholm LH, Ekbom T, Dash C, Isaacsson A, Schersten B. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies. J Intern Med. 1996;240:13-22.
32. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population. Am J Med. 1996;101:627-634.
33. Davidson M, McKenny J, Stein E, et al. Comparison on one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.
34. Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Am J Cardiol. 1997;79:893-896.
35. Bertrand ME, McFadden EP, Fruchart JC, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol. 1997; 30:863-869.
36. Bestehorn HP, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. Eur Heart J. 1997;18:226-234.
37. MAAS Investigators. Effect of simvastatin on coronary atheroma. Lancet. 1994;344:633-638.
38. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med. 1996;124:548-556.
39. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenousvein coronary-artery bypass grafts. N Engl J Med. 1997; 336:153-162.
40. Fleiss JL. Measures of effect size for categorical data. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NV: Russell Sage Foundation; 1994:245-260.
41. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment of Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
42. LaRosa JC. Unresolved Issues: Unanswered Questions: Proceedings from the Amstel Hotel Satellite Symposium: Controversies in the Determination of Cardiovascular Therapy. XXth Congress of the European Society of Cardiology; August 22-26, 1998; Vienna, Austria. In press.
43. Gaw A, Blauw GJ, Shepherd J, Murphy M. The PROSPER design: a prospective study of pravastatin in the elderly at risk. Paper presented at: International Congress on Vascular Prevention; May 5-8, 1998; Glasgow, Scotland.
44. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA. 1998;280:605-613.
45. LaRosa JC. Cholesterol management in women and the elderly. J Intern Med. 1997;157:961-968.